Factors that influence the willingness of young adults in Dar es Salaam, Tanzania, to participate in phase I/II HIV vaccine trials

Background: Despite the successful conduct of three Phase I/II HIV vaccine trials in Dar es Salaam, Tanzania, misperception around the trials has been reported. In this study, misperception means incorrect understanding that in Phase I/II HIV vaccine trial, the researchers infected the volunteers with HIV. We describe the magnitude of misperception around HIV vaccine trials and associated factors among participating communities in Dar es Salaam, Tanzania. Methods: We conducted a cross-sectional study that included 605 respondents aged ³18 years from the communities that participated in Phase I/II HIV vaccine trials. These communities comprised of youths, Police and Prison officers. Respondents were interviewed using a pre-tested questionnaire on socio-demographic characteristics, HIV knowledge, and responses to HIV vaccine trial related questions. Results: Of the 605 respondents, 156 (26%) had misperception that the researchers infected the volunteers with HIV during the trials, while 58% weren’t sure whether the researchers infected the volunteers with the HIV or not. Awareness about progress in HIV vaccine development (adjusted risk ratio (RR)=1.50; 95% CI=1.11 – 2.04), participation in an HIV vaccine sensitization meeting (adjusted RR=1.50; 95% CI=1.14-1.97) and advanced secondary education (adjusted RR=1.92; 95% CI=1.19 – 3.09) were associated with an increased likelihood of having the misperception that researchers infected the volunteers. Nevertheless, the majority (94.5%) of respondents showed a willingness to know more about ongoing HIV vaccine studies while about 44.3% had reservations of taking part in HIV vaccine trials due to fear of getting HIV from the vaccine. Conclusions: The misperception that researchers infected volunteers with HIV in Phase I/II trial is significant and was associated with respondents’ awareness about HIV vaccine development, participation in sensitization meetings and advanced education. Partial knowledge about HIV vaccine trials was of note. Future HIV vaccine trials should strive to address the knowledge gap.

Download Full-text

Contraceptive Use in Women Enrolled into Preventive HIV Vaccine Trials: Experience from a Phase I/II Trial in East Africa

PLoS ONE ◽

10.1371/journal.pone.0005164 ◽

2009 ◽

Vol 4 (4) ◽

pp. e5164 ◽

Cited By ~ 15

Author(s):

Hannah Kibuuka ◽

David Guwatudde ◽

Robert Kimutai ◽

Lucas Maganga ◽

Leonard Maboko ◽

...

Keyword(s):

Phase I ◽

East Africa ◽

Contraceptive Use ◽

Hiv Vaccine ◽

Hiv Vaccine Trials ◽

Vaccine Trials

Download Full-text

Sexual risk behaviour of the first cohort undergoing screening for enrolment into Phase I/II HIV vaccine trials in South Africa

International Journal of STD & AIDS ◽

10.1258/ijsa.2008.008207 ◽

2009 ◽

Vol 20 (2) ◽

pp. 95-101 ◽

Cited By ~ 7

Author(s):

K M Andersson ◽

R M Van Niekerk ◽

L M Niccolai ◽

O N Mlungwana ◽

I M Holdsworth ◽

...

Keyword(s):

South Africa ◽

Phase I ◽

Sexual Risk ◽

Risk Behaviour ◽

Hiv Vaccine ◽

Sexual Risk Behaviour ◽

Hiv Vaccine Trials ◽

Vaccine Trials

Download Full-text

Overweight BMI and Alcohol Use Are Associated with Immune Responses in Phase I HIV Vaccine Trials

AIDS Research and Human Retroviruses ◽

10.1089/aid.2014.5399.abstract ◽

2014 ◽

Vol 30 (S1) ◽

pp. A186-A187

Author(s):

Roger Bayingana ◽

Gaudensia Mutua ◽

Juliet Mpendo ◽

William Kilembe ◽

Gloria Omosa-Manyonyi ◽

...

Keyword(s):

Alcohol Use ◽

Immune Responses ◽

Phase I ◽

Hiv Vaccine ◽

Hiv Vaccine Trials ◽

Vaccine Trials

Download Full-text

Gender aspects on HIV prevention efforts and participation in HIV vaccine trials among Police officers in Dar es Salaam, Tanzania

BMC Public Health ◽

10.1186/s12889-018-5835-5 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 1

Author(s):

Edith A. M. Tarimo ◽

Deodatus C. V. Kakoko ◽

Thecla W. Kohi ◽

Muhammad Bakari ◽

Eric Sandstrom ◽

...

Keyword(s):

Hiv Prevention ◽

Police Officers ◽

Dar Es Salaam ◽

Hiv Vaccine ◽

Hiv Vaccine Trials ◽

Vaccine Trials ◽

Gender Aspects

Download Full-text

Willingness to Participate in Hypothetical HIV Vaccine Trial and Associated Factors among People Who Inject Drugs in Dar es Salaam, Tanzania

BioMed Research International ◽

10.1155/2020/8507981 ◽

2020 ◽

Vol 2020 ◽

pp. 1-9

Author(s):

Masunga K. Iseselo ◽

Edith A. M. Tarimo ◽

Eric Sandstrom ◽

Asli Kulane

Keyword(s):

Associated Factors ◽

People Who Inject Drugs ◽

Hiv Transmission ◽

Dar Es Salaam ◽

Education Level ◽

Sexual Partners ◽

Hiv Vaccine ◽

Willingness To Participate ◽

Hiv Vaccine Trials ◽

Vaccine Trials

This study is aimed at assessing the willingness to participate in the HIV vaccine trials and the associated factors among people who inject drugs (PWIDs) in Tanzania. Information about the willingness to participate and the associated factors was collected using interviewer-administered questionnaires at the medication treatment for opioid use disorder (MOUD) clinic in Dar es Salaam. Data analysis was performed using the IBM SPSS Statistic 20. The mean age of respondents was 36.7, and the standard deviation (SD) was ±7.2. The majority of respondents (68%) had primary education, and a high proportion of them were single (61.5%). More than one-third (37.9%) shared needles and syringes. Most (87.3%) had more than three sexual partners, and almost half (51.4%) did not use condoms during sexual intercourse with nonregular partners. About 63% had knowledge of HIV transmission while 27% had heard about HIV vaccine trials. Generally, 76% of the respondents expressed willingness to participate in future HIV vaccine trials regardless of prior knowledge of HIV vaccine trials. Willingness to participate in HIV vaccine trials was not associated with education level, people living with, knowledge about HIV transmission, awareness of HIV vaccine trials, sharing of syringe/needles, and number of sexual partners. Only older age (OR=1.6, 95%CI=1.01, 2.6) and condom use (OR=0.49, 95%CI=0.26, 0.97) showed an association with willingness. However, after performing logistic regression with factors at p value ≤ 0.2 to ascertain the other factors on the effects of age, condom use, education level, and sharing of needles/syringes, the results were not statistically significant. Although participants reported a high willingness to participate in hypothetical HIV vaccine trials, no definitive conclusion can be drawn about the associated factors. Further studies with intensive educational programs are needed to investigate the factors on willingness to participate in actual HIV vaccine trials among PWIDs.

Download Full-text

Enrollment of Racial/Ethnic Minorities in NIAID-Funded Networks of HIV Vaccine Trials in the United States, 1988 to 2002

Public Health Reports ◽

10.1177/003335490512000509 ◽

2005 ◽

Vol 120 (5) ◽

pp. 543-548 ◽

Cited By ~ 27

Author(s):

Gaston Djomand ◽

Joanna Katzman ◽

Dante diTommaso ◽

Michael G. Hudgens ◽

George W. Counts ◽

...

Keyword(s):

Phase I ◽

Ethnic Minority ◽

Phase Ii ◽

Hiv Vaccine ◽

Phase I Trials ◽

Hiv Vaccine Trials ◽

Vaccine Trials ◽

Minority Participants ◽

Racial Ethnic ◽

The U.S

Objective. The purpose of this study was to analyze enrollment of racial/ethnic minorities in Phase I and Phase II HIV vaccine trials in the U.S. conducted by National Institute of Allergy and Infectious Diseases (NIAID)-funded networks from 1988 to 2002. Methods. A centralized database was searched for all NIAID-funded networks of HIV vaccine trial enrollment data in the U.S. from 1988 through 2002. The authors reviewed data from Phase I or Phase II preventive HIV vaccine trials that included HIV-1 uninfected participants at low to moderate or high risk for HIV infection based on self-reported risk behaviors. Of 66 identified trials, 55 (52 Phase I, 3 Phase II) met selection criteria and were used for analyses. Investigators extracted data on participant demographics using statistical software. Results. A total of 3,731 volunteers enrolled in U.S. NIAID-funded network HIV vaccine trials from 1988 to 2002. Racial/ethnic minority participants represented 17% of the overall enrollment. By pooling data across all NIAID-funded networks from 1988 to 2002, the proportion of racial/ethnic minority participants was significantly greater (Fisher's exact test p-value <0.001) in Phase II trials (278/1,061 or 26%) than in Phase I trials (347/2,670 or 13%). By generalized estimating equations, the proportion of minorities in Phase I trials increased over time ( p=0.017), indicating a significant increase in racial/ethnic minority participants from 1988 to 2002. Conclusions. There has been a gradual increase in racial/ethnic minority participation in NIAID-funded network HIV vaccine trials in the U.S. since 1988. In the light of recent efficacy trial results, it is essential to continue to increase the enrollment of diverse populations in HIV vaccine research.

Download Full-text